A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Condition: Alopecia Areata Interventions: Drug: CTP-543, 8 mg BID; Drug: CTP-543, 12 mg BID; Drug: Placebo, BID Sponsor: Concert Pharmaceuticals Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials